ProShare Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-19,203
Closed -$99K 1722
2019
Q2
$99K Sell
19,203
-2,354
-11% -$10.6K ﹤0.01% 1533
2019
Q1
$78K Buy
21,557
+168
+0.8% +$728 ﹤0.01% 1591
2018
Q4
$131K Sell
21,389
-3,612
-14% -$22K ﹤0.01% 1438
2018
Q3
$146K Sell
25,001
-567
-2% -$2.83K ﹤0.01% 1642
2018
Q2
$109K Buy
25,568
+397
+2% +$2K ﹤0.01% 1701
2018
Q1
$111K Sell
25,171
-4,139
-14% -$18.5K ﹤0.01% 1626
2017
Q4
$154K Buy
29,310
+2,303
+9% +$14.1K ﹤0.01% 1684
2017
Q3
$166K Buy
27,007
+1,685
+7% +$10.7K ﹤0.01% 1299
2017
Q2
$183K Buy
25,322
+1,709
+7% +$10.5K ﹤0.01% 1359
2017
Q1
$125K Sell
23,613
-6,217
-21% -$42K ﹤0.01% 1497
2016
Q4
$214K Buy
29,830
+4,203
+16% +$34K ﹤0.01% 1561
2016
Q3
$240K Sell
25,627
-4,765
-16% -$39.6K ﹤0.01% 1257
2016
Q2
$192K Buy
30,392
+1,038
+4% +$6.68K ﹤0.01% 1432
2016
Q1
$162K Sell
29,354
-3,114
-10% -$11.7K ﹤0.01% 1454
2015
Q4
$181K Buy
32,468
+2,970
+10% +$19.6K ﹤0.01% 1565
2015
Q3
$250K Sell
29,498
-2,136
-7% -$36.1K ﹤0.01% 1216
2015
Q2
$478K Sell
31,634
-1,873
-6% -$27K 0.01% 1118
2015
Q1
$536K Buy
33,507
+4,357
+15% +$77.5K 0.01% 1141
2014
Q4
$519K Buy
+29,150
New +$363K 0.01% 1182
2014
Q3
Sell
-11,905
Closed -$186K 2404
2014
Q2
$186K Buy
+11,905
New +$169K ﹤0.01% 2204

Other funds holding PETX

ProShare Advisors's PETX Position: Q3 2019 in Review

ProShare Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 19,203 shares — an estimated $99K sold.

ProShare Advisors first reported a position in PETX in Q2 2014 and held it in 20 quarters. The position peaked at $536K in Q1 2015. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

  • ProShare Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • ProShare Advisors sold 19,203 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $99K.
  • ProShare Advisors first reported a position in Aratana Therapeutics, Inc. in Q2 2014 and held it in 20 quarters.
  • ProShare Advisors's Aratana Therapeutics, Inc. position peaked at $536K in Q1 2015.
  • 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on ProShare Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.